Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India (SOLID)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01292018
First received: January 31, 2011
Last updated: February 20, 2013
Last verified: February 2013

January 31, 2011
February 20, 2013
February 2011
Not Provided
Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01292018 on ClinicalTrials.gov Archive Site
  • Proportion of dyslipidemia control rate according to american diabetes Association (ADA) 2010 criteria by age and gender [ Designated as safety issue: No ]
  • Control of dyslipidemia by Lipid Lowering Drugs (LLDs) drugs alone or combination [ Designated as safety issue: No ]
  • Control of dyslipidemia by all commercial available brands hypolipidemics drugs [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India
A Non Interventional, Cross Sectional, Epidemiological Study on the Management of Dyslipidemia in Type 2 DM Adult Patients in India
The purpose of study to assess the control of dyslipidemia in the Indian diabetic population treated with any hypolipidemic agent.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Description:
Lipid profile ( Low Density Lipoproteins(LDL), High Density Lipoprotein (HDL), Triglycerides & Total cholesterol) Blood Glucose Measurements (Fasting Plasma Glucose)
Non-Probability Sample
Type 2 Diabetics with dyslipidemia on stable dose of Lipid Lowering Drugs(LLDs).
  • Dyslipidemia
  • Type 2 Diabetes Mellitus
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5400
February 2012
Not Provided

Inclusion Criteria:

  • Adult who is a known Type 2 diabetic as per the ADA 2010 criteria OR controlled diabetic (taking any antidiabetic medication)
  • Patients in the study will have been on lipid lowering drugs at a stable dose for the last three months before the designated study visit.

Exclusion Criteria:

  • Type 1 diabetic patients
  • Patients with a history of hepatic or renal diseases
  • Hypertension due to organic diseases
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01292018
NIS-CIN-DUM-2010/1
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP